Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma

[1]  Juping Yuan,et al.  The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy , 2019, Cancers.

[2]  P. Zinzani,et al.  Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations , 2018, Leukemia & lymphoma.

[3]  E. Campo,et al.  Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma , 2017, Journal of Hematology & Oncology.

[4]  E. Giné,et al.  Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. , 2016, Cancer cell.

[5]  L. Crawford,et al.  The role of the CCN family of proteins in blood cancers , 2016, Journal of Cell Communication and Signaling.

[6]  C. Lau,et al.  p27 Is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma. , 2016, Cancer research.

[7]  R. Advani,et al.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms. , 2016, Blood.

[8]  A. Rosenwald,et al.  Targeting protein kinase C in mantle cell lymphoma , 2016, British journal of haematology.

[9]  E. Winterhager,et al.  CCN1 (CYR61) and CCN3 (NOV) signaling drives human trophoblast cells into senescence and stimulates migration properties , 2016, Cell adhesion & migration.

[10]  M. Yano,et al.  Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. , 2015, World journal of gastroenterology.

[11]  Jiang F Zhong,et al.  Current approaches and advance in mantle cell lymphoma treatment. , 2015, Stem cell investigation.

[12]  C. Guerra,et al.  Loss of p27Kip1 promotes metaplasia in the pancreas via the regulation of Sox9 expression , 2015, Oncotarget.

[13]  A. Goy,et al.  A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. , 2015, Clinical lymphoma, myeloma & leukemia.

[14]  R. Mathur,et al.  Targeting Wnt pathway in mantle cell lymphoma-initiating cells , 2015, Journal of Hematology & Oncology.

[15]  U. Kees,et al.  The role of CCN family genes in haematological malignancies , 2015, Journal of Cell Communication and Signaling.

[16]  Javier León,et al.  Myc and cell cycle control. , 2015, Biochimica et biophysica acta.

[17]  Michael L. Wang,et al.  Molecular Signatures of Tumor-Initiating Cells Unveil Wnt Pathway As a Therapeutic Target in Mantle Cell Lymphoma , 2014 .

[18]  James M. Roberts,et al.  Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy , 2014, Oncotarget.

[19]  J. Stewart,et al.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. , 2014, Blood.

[20]  G. Roodman.  CCN1: a sticky issue in myeloma. , 2014, Blood.

[21]  Jing Pan,et al.  Inhibiting CCN1 blocks AML cell growth by disrupting the MEK/ERK pathway , 2014, Cancer Cell International.

[22]  F. Jakob,et al.  Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells , 2014, Cell Communication and Signaling.

[23]  G. Haines,et al.  Matricellular protein CCN1 (CYR61) expression is associated with high-grade ductal carcinoma in situ. , 2014, Human pathology.

[24]  M. DePamphilis,et al.  Cytoplasmic Localization of p21 Protects Trophoblast Giant Cells from DNA Damage Induced Apoptosis , 2014, PloS one.

[25]  Sushanta K Banerjee,et al.  Pancreatic Tumor Cell Secreted CCN1/Cyr61 Promotes Endothelial cell migration and Aberrant Neovascularization , 2014, Scientific Reports.

[26]  Hyungjoo Kim,et al.  Cyr61 Expression is associated with prognosis in patients with colorectal cancer , 2014, BMC Cancer.

[27]  A. Leask,et al.  ALK5 inhibition blocks TGFβ-induced CCN1 expression in human foreskin fibroblasts , 2014, Journal of Cell Communication and Signaling.

[28]  Ming-Tsan Lin,et al.  Cyr61/CTGF/Nov family proteins in gastric carcinogenesis. , 2014, World journal of gastroenterology.

[29]  Antonio Martínez,et al.  Antitumoral Activity of Lenalidomide in In Vitro and In Vivo Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27KIP1 Complexes , 2013, Clinical Cancer Research.

[30]  Manel Juan,et al.  Landscape of somatic mutations and clonal evolution in mantle cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[31]  B. Dörken,et al.  Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down‐regulation of Mcl‐1 in mantle cell lymphoma , 2013, International journal of cancer.

[32]  Jung-Sung Sung,et al.  The matricellular protein CCN1 suppresses lung cancer cell growth by inducing senescence via the p53/p21 pathway , 2013, Journal of cellular biochemistry.

[33]  E. Zucca,et al.  Toward new treatments for mantle-cell lymphoma? , 2013, The New England journal of medicine.

[34]  L. Lau,et al.  Degradome Products of the Matricellular Protein CCN1 as Modulators of Pathological Angiogenesis in the Retina* , 2013, The Journal of Biological Chemistry.

[35]  A. García-García,et al.  The role of p21Waf1/CIP1 as a Cip/Kip type cell-cycle regulator in oral squamous cell carcinoma (Review). , 2013, Medicina oral, patologia oral y cirugia bucal.

[36]  S. Crispi,et al.  The Dual Role Played by p21 May Influence the Apoptotic or Anti-Apoptotic Fate in Cancer , 2012 .

[37]  E. Meuillet,et al.  The matrix protein CCN1/CYR61 is required for αVβ5‐mediated cancer cell migration , 2012, Cell Biochemistry and Function.

[38]  P. V. Van Veldhuizen,et al.  The Matricellular Protein CCN1/Cyr61 Is a Critical Regulator of Sonic Hedgehog in Pancreatic Carcinogenesis* , 2012, The Journal of Biological Chemistry.

[39]  E. Campo,et al.  Molecular pathogenesis of mantle cell lymphoma. , 2012, The Journal of clinical investigation.

[40]  X. Guan,et al.  A crosstalk imbalance between p27(Kip1) and its interacting molecules enhances breast carcinogenesis. , 2012, Cancer biotherapy & radiopharmaceuticals.

[41]  T. Pospelova,et al.  Cyclin-dependent kinase inhibitor p21Waf1: Contemporary view on its role in senescence and oncogenesis , 2012, Biochemistry (Moscow).

[42]  A. Stenzl,et al.  High cytoplasmic expression of p27Kip1 is associated with a worse cancer‐specific survival in clear cell renal cell carcinoma , 2012, BJU international.

[43]  W. Ding,et al.  Cyr61/CCN1 Is Regulated by Wnt/β-Catenin Signaling and Plays an Important Role in the Progression of Hepatocellular Carcinoma , 2012, PloS one.

[44]  S. Joshi,et al.  Ritonavir exhibits limited efficacy as a single agent in treating aggressive mantle cell lymphoma , 2012 .

[45]  Yi Zhang,et al.  Cell cycle regulation by carboxylated multiwalled carbon nanotubes through p53-independent induction of p21 under the control of the BMP signaling pathway. , 2012, Chemical research in toxicology.

[46]  E. Giné,et al.  Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease , 2012, Leukemia.

[47]  M. Martinka,et al.  Prognostic Significance of Cytoplasmic p27 Expression in Human Melanoma , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[48]  L. Lau.  CCN1/CYR61: the very model of a modern matricellular protein , 2011, Cellular and Molecular Life Sciences.

[49]  Mitchell R. Smith.  Should there be a standard therapy for mantle cell lymphoma? , 2011, Future oncology.

[50]  A. Wiestner,et al.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. , 2011, Blood.

[51]  C. Oshima,et al.  Expression of p27, p21WAF/Cip1, and p16INK4a in Normal Oral Epithelium, Oral Squamous Papilloma, and Oral Squamous Cell Carcinoma , 2010 .

[52]  T. Hunter,et al.  Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors , 2010, Cell cycle.

[53]  E. Platz,et al.  Extracellular matrix associated protein CYR61 is linked to prostate cancer development. , 2010, The Journal of urology.

[54]  L. Lau,et al.  Matricellular Protein CCN1 Activates a Proinflammatory Genetic Program in Murine Macrophages , 2010, The Journal of Immunology.

[55]  A. Al-Attar,et al.  Cytoplasmic p27 Expression is an Independent Prognostic Factor in Ovarian Cancer , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[56]  M. Bar‐eli,et al.  Silencing cAMP-response Element-binding Protein (CREB) Identifies CYR61 as a Tumor Suppressor Gene in Melanoma* , 2009, The Journal of Biological Chemistry.

[57]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[58]  B. Perbal.  Alternative splicing of CCN mRNAs …. it has been upon us , 2009, Journal of Cell Communication and Signaling.

[59]  A. Irvine,et al.  CCN3--a key regulator of the hematopoietic compartment. , 2009, Blood reviews.

[60]  R. P. Fisher,et al.  p27Kip1 Inhibits Cyclin D-Cyclin-Dependent Kinase 4 by Two Independent Modes , 2008, Molecular and Cellular Biology.

[61]  R. Lai,et al.  Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. , 2008, Blood.

[62]  D. Xie,et al.  Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells , 2008, British Journal of Cancer.

[63]  Carl W. Miller,et al.  Functional domains of CCN1 (Cyr61) regulate breast cancer progression. , 2008, International journal of oncology.

[64]  B. Park,et al.  p21 and p27: roles in carcinogenesis and drug resistance , 2008, Expert Reviews in Molecular Medicine.

[65]  R. Assoian,et al.  Growth control by intracellular tension and extracellular stiffness. , 2008, Trends in cell biology.

[66]  R. Agarwal,et al.  Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype , 2008, Cell cycle.

[67]  P. Schafer,et al.  The ratio of cyclin D1/p21kip baseline gene expression and SPARC gene expression can be potential predictors of non-Hodgkin's lymphoma (NHL) patient response to lenalidomide therapy , 2008 .

[68]  Jan Koster,et al.  Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. , 2008, Cancer research.

[69]  James M. Roberts,et al.  CDK inhibitors: cell cycle regulators and beyond. , 2008, Developmental cell.

[70]  James M. Roberts,et al.  A Mechanism Misregulating p27 in Tumors Discovered in a Functional Genomic Screen , 2007, PLoS genetics.

[71]  F. Jakob,et al.  The Matricellular Protein CYR61 Inhibits Osteoclastogenesis by a Mechanism Independent of αvβ3 and αvβ5 , 2007 .

[72]  Ming-Hsun Wu,et al.  Elevated Expression of Cyr61 Enhances Peritoneal Dissemination of Gastric Cancer Cells through Integrin α2β1* , 2007, Journal of Biological Chemistry.

[73]  S. Yamada,et al.  Expression of CCN1 (CYR61) in developing, normal, and diseased human kidney. , 2007, American journal of physiology. Renal physiology.

[74]  B. Datnow,et al.  Relocalized p27Kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. , 2007, Cancer research.

[75]  Ying Chen,et al.  Functional properties and intracellular signaling of CCN1/Cyr61 , 2007, Journal of cellular biochemistry.

[76]  J. Chirgwin,et al.  The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. , 2007, Cancer letters.

[77]  K. Schulze-Osthoff,et al.  p21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation. , 2006, Cancer research.

[78]  James M. Roberts,et al.  Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer , 2006, Proceedings of the National Academy of Sciences.

[79]  S. Saule,et al.  Nuclear addressing provides a clue for the transforming activity of amino‐truncated CCN3 proteins , 2006, Journal of cellular biochemistry.

[80]  E. Campo,et al.  Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. , 2006, Leukemia research.

[81]  A. Montag,et al.  CCN1/Cyr61 Is Regulated by the Canonical Wnt Signal and Plays an Important Role in Wnt3A-Induced Osteoblast Differentiation of Mesenchymal Stem Cells , 2006, Molecular and Cellular Biology.

[82]  R. Gascoyne,et al.  Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. , 2006, Leukemia research.

[83]  K. Caldwell,et al.  Identification of mitogen-activated protein kinase docking sites in enzymes that metabolize phosphatidylinositols and inositol phosphates , 2006, Cell Communication and Signaling.

[84]  A. Mauro,et al.  p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells , 2005, Molecular Cancer.

[85]  N. Hay,et al.  The matrix protein CCN1 (CYR61) induces apoptosis in fibroblasts , 2005, The Journal of cell biology.

[86]  U. Pendurthi,et al.  Proteolysis of CCN1 by plasmin: functional implications. , 2005, Cancer research.

[87]  Dong Xie,et al.  Ovarian Carcinomas: CCN Genes Are Aberrantly Expressed and CCN1 Promotes Proliferation of these Cells , 2005, Clinical Cancer Research.

[88]  Vikram Devgan,et al.  p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation. , 2005, Genes & development.

[89]  Z. Nemes,et al.  p21WAF1/CIP1 expression is a marker of poor prognosis in oral squamous cell carcinoma. , 2005, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[90]  L. Girard,et al.  Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. , 2005, Journal of the American College of Surgeons.

[91]  D. Griggs,et al.  A novel CYR61-triggered ‘CYR61-αvβ3 integrin loop’ regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway , 2005, Oncogene.

[92]  Carl W. Miller,et al.  Cyr61 Suppresses Growth of Human Endometrial Cancer Cells* , 2004, Journal of Biological Chemistry.

[93]  Y. Liu,et al.  Targeted Mutagenesis of the Angiogenic Protein CCN1 (CYR61) , 2004, Journal of Biological Chemistry.

[94]  D. Steinemann,et al.  Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519. , 2004, Cancer genetics and cytogenetics.

[95]  J. Y. Kim,et al.  Cytoplasmic Mislocalization of p27Kip1 Protein Is Associated with Constitutive Phosphorylation of Akt or Protein Kinase B and Poor Prognosis in Acute Myelogenous Leukemia , 2004, Cancer Research.

[96]  Carl W. Miller,et al.  Cyr61 suppresses the growth of non-small-cell lung cancer cells via the β-catenin–c-myc–p53 pathway , 2004, Oncogene.

[97]  Ming-Tsan Lin,et al.  Cyr61 Expression Confers Resistance to Apoptosis in Breast Cancer MCF-7 Cells by a Mechanism of NF-κB-dependent XIAP Up-Regulation* , 2004, Journal of Biological Chemistry.

[98]  Dong Xie,et al.  Cyr61 Is Overexpressed in Gliomas and Involved in Integrin-Linked Kinase-Mediated Akt and β-Catenin-TCF/Lef Signaling Pathways , 2004, Cancer Research.

[99]  Dong Xie,et al.  Levels of Expression of CYR61 and CTGF Are Prognostic for Tumor Progression and Survival of Individuals with Gliomas , 2004, Clinical Cancer Research.

[100]  M. Raffeld,et al.  Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. , 2003, Blood.

[101]  I. Roninson.  Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. , 2002, Cancer letters.

[102]  J. Langdon,et al.  Expression of type 2 nitric oxide synthase and p21 in oral squamous cell carcinoma. , 2002, International journal of oral and maxillofacial surgery.

[103]  N. Perkins.  Not Just a CDK Inhibitor: Regulation of Transcription by p21WAF1/CIP1/SDI1 , 2002, Cell cycle.

[104]  Carl W. Miller,et al.  Cyr61, a Member of CCN Family, Is a Tumor Suppressor in Non-Small Cell Lung Cancer* , 2001, The Journal of Biological Chemistry.

[105]  J. Rosenbloom,et al.  Regulation of Cyr61 gene expression by mechanical stretch through multiple signaling pathways. , 2001, American journal of physiology. Cell physiology.

[106]  I. Ng,et al.  Expression of p27KIP1 and p21WAF1/CIP1 in primary hepatocellular carcinoma: Clinicopathologic correlation and survival analysis , 2001 .

[107]  J. Nevins,et al.  The Rb/E2F pathway and cancer. , 2001, Human molecular genetics.

[108]  D. Santini,et al.  Quantitative p21WAF‐1/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators , 2001, International journal of cancer.

[109]  G. Scambia,et al.  p21WAF1/CIP1 protein expression in primary ovarian cancer. , 2000, International journal of oncology.

[110]  S. Alkan,et al.  Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma. , 2000, Archives of pathology & laboratory medicine.

[111]  S. Baldus,et al.  Prognostic impact of p21/waf1/cip1 in colorectal cancer , 2000, International journal of cancer.

[112]  A. Sewing,et al.  Cyclins D1 and D2 mediate Myc‐induced proliferation via sequestration of p27Kip1 and p21Cip1 , 1999, The EMBO journal.

[113]  L. Lau,et al.  Activation-dependent Adhesion of Human Platelets to Cyr61 and Fisp12/Mouse Connective Tissue Growth Factor Is Mediated through Integrin αIIbβ3 * , 1999, The Journal of Biological Chemistry.

[114]  B. Perbal.  Nuclear localisation of NOVH protein: a potential role for NOV in the regulation of gene expression. , 1999, Molecular pathology : MP.

[115]  H. Hsu,et al.  Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. , 1998, Journal of hepatology.

[116]  E. Campo,et al.  Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. , 1998, The American journal of pathology.

[117]  T. Nikaido,et al.  Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix , 1998, Cancer.

[118]  T. Yagi,et al.  Mutated p21WAF1/CIP1/SDI1 lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells , 1998, Oncogene.

[119]  M. Fukuoka,et al.  p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[120]  J. LaBaer,et al.  New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.

[121]  James M. Roberts,et al.  Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle , 1996, Science.

[122]  G. Peters,et al.  Cyclin D1 and prognosis in human breast cancer , 1996, International journal of cancer.

[123]  L. Lau,et al.  Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion , 1996, Molecular and cellular biology.

[124]  J. Bruner,et al.  Increased levels of p21WAF1/Cip1 in human brain tumors. , 1995, Oncogene.

[125]  H. Koeffler,et al.  Role of the cyclin-dependent kinase inhibitors in the development of cancer. , 1995, Blood.

[126]  Tony Hunter,et al.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 , 1994, Cell.

[127]  G. Hannon,et al.  The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA , 1994, Nature.

[128]  E. Campo,et al.  Mantle cell lymphoma: evolving management strategies. , 2015, Blood.

[129]  haematological malignancies , 2014 .

[130]  Ryan D. Morin,et al.  Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. , 2012, Blood.

[131]  Bei Wang,et al.  Cyr61/CCN1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response. , 2008, The international journal of biochemistry & cell biology.

[132]  O. O’Connor.  Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways. , 2007, Hematology. American Society of Hematology. Education Program.

[133]  T. Ugarova,et al.  Integrin alphaDbeta2, an adhesion receptor up-regulated on macrophage foam cells, exhibits multiligand-binding properties. , 2006, Blood.

[134]  Cell Communication and Signaling BioMed Central Review , 2006 .

[135]  N. Planque,et al.  A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis , 2003, Cancer Cell International.

[136]  G. Adamopoulos,et al.  p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. , 2001, Anticancer research.

[137]  S. Groshen,et al.  WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. , 1997, The American journal of pathology.

[138]  G. Peters,et al.  Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. , 1996, Advances in cancer research.

[139]  G. Baretton,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1998.0390 , 2022 .